News & Updates
Showing Multidisciplinary articles
Showing
Tamoxifen interruption for pregnancy feasible in young breast cancer survivors
A real-world Asian study presented at ESMO Asia 2025 supports temporary tamoxifen interruption for young breast cancer survivors who are considering pregnancy.
Tamoxifen interruption for pregnancy feasible in young breast cancer survivors
08 Jan 2026
Mortality risk elevated in UC patients with CAD
Ulcerative colitis (UC) patients with active coronary artery disease (CAD) appear to be at greater risk of mortality than those with Crohn’s disease (CD), suggest the results of a study presented at AIBD 2025.
Mortality risk elevated in UC patients with CAD
07 Jan 2026
Long-term anti-TNF use works wonders in moderate to severe IBD
The use of antitumour necrosis factor (anti-TNF) agents for at least 60 months is not only safe but also effective in the treatment of moderate to severe inflammatory bowel disease (IBD), according to a study presented at AIBD 2025.
Long-term anti-TNF use works wonders in moderate to severe IBD
07 Jan 2026
Does aspirin use improve outcomes in APS patients with arterial thrombosis?
The addition of low-dose aspirin to warfarin appears to increase the risk of major bleeding in patients with antiphospholipid syndrome (APS) but falls short in reducing all-cause mortality, according to a study presented at ASH 2025. Likewise, the rates of ischemic stroke and acute myocardial infarction are also higher among aspirin users.
Does aspirin use improve outcomes in APS patients with arterial thrombosis?
06 Jan 2026
Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6
In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).
